Schrödinger reported third-quarter 2026 total revenue of $64.5 million, up 19%, and raised its full-year 2026 ACV and drug discovery revenue guidance. The net loss widened to $37.7 million from $32.8 million, and the company corrected a American Society of Hematology abstract that wrongly described an ongoing SGR-1505 combination study. Shareholders see a higher top line and outlook alongside a larger loss.
Total revenue was $64.5 million, up from $54.3 million, with drug discovery revenue of $24.2 million helped by a Structure Therapeutics milestone payment.
Net loss was $37.7 million, or $0.50 per share, compared with a net loss of $32.8 million, or $0.45 per share, a year earlier.
2026 ACV guidance was raised to $222 million to $232 million, and drug discovery revenue guidance to $75 million to $85 million.
The company said it has not started a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities for the program.
Schrodinger's board designated Therese Abrams, its Vice President and Corporate Controller, as principal accounting officer effective March 8, 2026. Jenny Herman, the former Chief Accounting Officer and principal accounting officer, transitioned from that role on March 6, 2026, and will stay employed through April 10, 2026 to ensure a smooth handover. This is an administrative change in the finance team that does not alter reported results or guidance.
Therese Abrams, 42, a certified public accountant, was designated principal accounting officer effective March 8, 2026
Abrams has served as Vice President, Corporate Controller since July 2025 and has been with the company since 2013
Jenny Herman transitioned from Chief Accounting Officer and principal accounting officer on March 6, 2026
Herman remains employed through April 10, 2026 to ensure a smooth transition
Schrödinger reported fourth-quarter and full-year 2025 results, with full-year total revenue up 23.3% and net loss narrowing from $187.1 million to $103.3 million. Fourth-quarter total revenue fell 1.2%, and the company said it is accelerating a shift to ratable hosted software revenue that it expects to reduce reported software revenue in the short to medium term.
Full-year 2025 total revenue was $255.9 million, up 23.3%; software revenue was $199.5 million, up 10.6%.
Fourth-quarter 2025 total revenue was $87.2 million, down 1.2%; fourth-quarter net income was $32.5 million versus a net loss of $40.2 million a year earlier.
2026 outlook calls for software ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million.
The company targets positive adjusted EBITDA by the end of 2028.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.